Revised Procedures for Non-Disclosure Agreements (NDA)

 

NEW -  Important Information for Investigators with International Collaborations

Revised Procedures for Non-Disclosure Agreements (NDA)

In an effort to reduce the time from request to execution of all clinical trial-related non-disclosure agreements (NDA) the Office of Technology Licensing and Industry Relations (OTLIR) has revised the procedure by which all clinical trial-related NDAs are being processed.  OTLIR thanks you for your compliance with the following procedure.  

1- Effective immediately, all requests for clinical trial-related NDAs must be sent to sbu_nda@stonybrook.edu along with an editable copy of the NDA and the name of the clinician that will be receiving confidential information under the NDA.  Please note, that if sbu_nda@stonybrook.edu is not copied on your request, your agreement may not be processed in a timely fashion.  

2- Effective Monday, March 18, 2019, clinicians will no longer be required to sign clinical trial-related NDAs as "read and understood" or "read and acknowledged."  However, the appropriate clinician will be copied on OTLIR correspondence reporting/providing a copy of the fully-executed clinical trial NDA.  Note this pertains only to clinical trial NDAs, not to other NDAs, which still require a "read and understood' acknowledgement.

Go to top